Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. was established in April 2009. It is a high-tech biopharmaceutical enterprise focusing on the research, development and production of peptide drugs and chemical drugs. The company is located in Jiangyin High-tech Development Zone, Jiangsu Province, and is a national high-tech enterprise. There are wholly-owned R&D subsidiaries Changchun ProteLight Pharmaceutical & Biotechnology Co., Ltd. and Nanjing Denovo Pharmaceutical Technology Co., Ltd., as well as subsidiaries Jiangsu Putai Pharmaceutical Technology Co., Ltd. and ProteLight Medical Holdings (Hong Kong) Co., Ltd.Explore More →
OUR SCIENCE AND PIPELINE
Established a very competitive peptide drug pipeline led by first-in-class anti-infective agents and anti-cancer drugs
R&D CenterThe company currently has multiple national Class 1 innovative drug research projects and dozens of patents, including PCT international invention patents, US and EU invention patents, Chinese invention patents, utility model and appearance patents, etc.Explore More +
Targets & Mechanisms of actionThe company currently has multiple varieties of national Class 1 innovative drugs under development, with dozens of patents, including PCT international invention patents, US and EU invention patents, etc.Explore More +
PipelineThe company continues to be oriented towards innovation and internationalization, increasing investment in research and development and the introduction of scientific research personnel.Explore More +
With technological innovation as the power, serving human health!
October 2023, Healthcare Executive Magzine released the lists of “Top 100 Chinese Pharmaceutical Innovative Enterprises in 2023” and “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”.
October 2023, Healthcare Executive Magzine released the lists of “Top 100 Chinese Pharmaceutical Innovative Enterprises in 2023” and “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”.READ MORE
Jiangsu Protelight Pharmaceutical Biotechnology Co., Ltd. successfully passed the certification of the ISO9001 quality management systemREAD MORE
Recently, Jiangsu ProteLight pharmaceutical & Biotechnology Co., Ltd. (abbreviated as: ProteLight Pharma) announced that the Antimicrobial Peptide PL-18 Suppository with independent intellectual property rights as first-in-class new drug has received Clinical trial approval from CDE in China and passed ethical review. Now, the project will launch Phase Ⅰ clinical study in China.READ MORE
ProteLight Pharma announced that its PL-18 suppository, the Chinese national category I new drug, a novel antimicrobial peptide, has passed ethical review by the Australian Therapeutic Goods Administration (TGA), and will start its first human clinical study in Australia.READ MORE